Last reviewed · How we verify
Wobenzym® plus
Wobenzym plus is a proteolytic enzyme combination that reduces inflammation and supports immune modulation through enzymatic breakdown of inflammatory mediators and immune complexes.
Wobenzym plus is a proteolytic enzyme combination that reduces inflammation and supports immune modulation through enzymatic breakdown of inflammatory mediators and immune complexes. Used for Inflammatory and degenerative joint conditions, Post-operative swelling and inflammation, Immune support and inflammation management.
At a glance
| Generic name | Wobenzym® plus |
|---|---|
| Also known as | manufacturing authorisation number DE_BE_01_MIA_2012_0034/5373/1 - MUCOS/4 |
| Sponsor | Mucos Pharma GmbH & Co. KG |
| Drug class | Proteolytic enzyme combination |
| Modality | Small molecule |
| Therapeutic area | Immunology / Inflammation |
| Phase | FDA-approved |
Mechanism of action
The product contains a blend of proteolytic enzymes (bromelain, papain, trypsin, chymotrypsin) and other cofactors that work to digest inflammatory proteins and immune complexes in the body. These enzymes are believed to modulate the inflammatory response and enhance immune function by promoting the clearance of circulating immune complexes and reducing pro-inflammatory mediators. The mechanism is thought to support the body's natural anti-inflammatory and immune-regulating processes.
Approved indications
- Inflammatory and degenerative joint conditions
- Post-operative swelling and inflammation
- Immune support and inflammation management
Common side effects
- Gastrointestinal upset
- Allergic reactions (rare)
- Mild digestive discomfort
Key clinical trials
- Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment With Bromelain, Trypsin and Rutoside Versus Placebo in Subjects With OsTeoarthritis (NA)
- Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance (PHASE3)
- Multi-Center Study Evaluating the Efficacy of Wobenzym(R)N in Treating Knee Osteoarthritis (PHASE2, PHASE3)
- Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wobenzym® plus CI brief — competitive landscape report
- Wobenzym® plus updates RSS · CI watch RSS
- Mucos Pharma GmbH & Co. KG portfolio CI